The French company NicOx reacquired the rights to experimental glaucoma drug PF-03187207 from Pfizer.  As part of the agreement, Pfizer has granted NicOx the right to access and use certain proprietary Xalatan® (latanoprost) data as well as temporary technical support to aid the transition.

The drug PF-03187207 has already completed two Phase II studies in patients with open-angle glaucoma and ocular hypertension.  In those trials PF-03187207 failed to meet the primary endpoint and Pfizer decided not to continue to late-stage trials. NicOx still believes that PF-03187207 has the potential to become an important new treatment option for patients with glaucoma. NicOx is now looking for third-party partnerships for further development of PF-03187207 into Phase III trials.

In addition, Pfizer will receive two milestone payments — the first linked to approval of the agent in the US, European Union and Japan and the second on reaching sales levels—as well as royalties on future sales. NicOx also regains the rights to a number of research- stage nitric oxide-donating compounds for the potential treatment of glaucoma and diabetic retinopathy.

Read ^[1] the release.